The Role of Conduction System Pacing in Heart Failure: Current Evidence and Future Directions.

IF 2 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Hadrian Hoang-Vu Tran, Audrey Thu, Anu Radha Twayana, Axel Fuertes, Marco Gonzalez, Marina Basta, Ashwini Mahadevaiah, Krutagni Adwait Mehta, Damien Islek, Maggie James, William H Frishman, Wilbert S Aronow
{"title":"The Role of Conduction System Pacing in Heart Failure: Current Evidence and Future Directions.","authors":"Hadrian Hoang-Vu Tran, Audrey Thu, Anu Radha Twayana, Axel Fuertes, Marco Gonzalez, Marina Basta, Ashwini Mahadevaiah, Krutagni Adwait Mehta, Damien Islek, Maggie James, William H Frishman, Wilbert S Aronow","doi":"10.1097/CRD.0000000000000993","DOIUrl":null,"url":null,"abstract":"<p><p>Conduction system pacing (CSP), including His bundle pacing and left bundle branch area pacing, offers a promising approach to treating heart failure (HF) with conduction system disease. This review examines the evidence supporting CSP as an alternative to traditional biventricular pacing in improving outcomes for HF patients. Studies were reviewed focusing on CSP's clinical efficacy in patients with left bundle branch block (LBBB) and those who are nonresponders to cardiac resynchronization therapy. Findings suggest that CSP enhances electrical and mechanical synchronization, improving left ventricular ejection fraction, reducing QRS duration, and leading to better clinical outcomes, including decreased HF-related hospitalizations and reduced all-cause mortality. Despite these benefits, technical challenges such as lead placement and device-related complications remain. The review concludes that CSP may offer significant advantages over conventional cardiac resynchronization therapy, particularly in patients with persistent conduction delays or myocardial scar. However, larger randomized controlled trials are needed to validate the long-term efficacy and safety of CSP across diverse patient populations. Future advancements in pacing technologies and personalized treatment strategies are expected to further refine CSP's role in HF management.</p>","PeriodicalId":9549,"journal":{"name":"Cardiology in Review","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology in Review","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CRD.0000000000000993","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Conduction system pacing (CSP), including His bundle pacing and left bundle branch area pacing, offers a promising approach to treating heart failure (HF) with conduction system disease. This review examines the evidence supporting CSP as an alternative to traditional biventricular pacing in improving outcomes for HF patients. Studies were reviewed focusing on CSP's clinical efficacy in patients with left bundle branch block (LBBB) and those who are nonresponders to cardiac resynchronization therapy. Findings suggest that CSP enhances electrical and mechanical synchronization, improving left ventricular ejection fraction, reducing QRS duration, and leading to better clinical outcomes, including decreased HF-related hospitalizations and reduced all-cause mortality. Despite these benefits, technical challenges such as lead placement and device-related complications remain. The review concludes that CSP may offer significant advantages over conventional cardiac resynchronization therapy, particularly in patients with persistent conduction delays or myocardial scar. However, larger randomized controlled trials are needed to validate the long-term efficacy and safety of CSP across diverse patient populations. Future advancements in pacing technologies and personalized treatment strategies are expected to further refine CSP's role in HF management.

传导系统起搏在心力衰竭中的作用:目前的证据和未来的方向。
传导系统起搏(CSP),包括他束起搏和左束分支区域起搏,是治疗传导系统疾病心衰(HF)的一种很有前途的方法。本综述探讨了支持CSP替代传统双心室起搏改善心衰患者预后的证据。研究回顾了CSP在左束支传导阻滞(LBBB)患者和对心脏再同步化治疗无反应的患者中的临床疗效。研究结果表明,CSP增强电和机械同步,改善左心室射血分数,缩短QRS持续时间,并导致更好的临床结果,包括减少hf相关住院和降低全因死亡率。尽管有这些好处,但技术上的挑战,如引线放置和设备相关的并发症仍然存在。该综述得出结论,CSP可能比传统的心脏再同步化治疗具有显著优势,特别是对于持续性传导延迟或心肌瘢痕的患者。然而,需要更大规模的随机对照试验来验证CSP在不同患者群体中的长期疗效和安全性。未来起搏技术和个性化治疗策略的进步有望进一步完善CSP在心衰治疗中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiology in Review
Cardiology in Review CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
4.60
自引率
0.00%
发文量
76
审稿时长
>12 weeks
期刊介绍: The mission of Cardiology in Review is to publish reviews on topics of current interest in cardiology that will foster increased understanding of the pathogenesis, diagnosis, clinical course, prevention, and treatment of cardiovascular disorders. Articles of the highest quality are written by authorities in the field and published promptly in a readable format with visual appeal
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信